LGC Acquires German Quality Controls Maker DiaMex
Posted on 05 Dec 2024
LGC (London, UK) has made an addition to its growing global clinical diagnostics and genomics portfolio by acquiring DiaMex (Heidelberg, Germany), a manufacturer of third-party serology and molecular quality controls used in clinical laboratories and blood banks across the world.
DiaMex is known for delivering top-quality controls, with a proven track record of successful product development achieved through collaboration with strategic partners. Over the past 13 years, DiaMex has offered a comprehensive range of third-party serology controls to its customers, and more recently, has expanded its offerings to include the development and commercialization of molecular controls.
LGC is a global leader in life science tools, committed to collaborating with customers to provide solutions that address critical challenges in diagnosing, treating, feeding, and protecting the growing global population. With over 180 years of scientific expertise, LGC works alongside the scientific community to confront some of the world’s most complex problems, including global health crises, advancements in precision medicine, and improving the safety of food, medicines, and the environment. Operating in 14 countries, LGC’s products and services are essential to industries that ensure the safety of public health, food, water, and medicine. LGC’s solutions assist its diverse customer base—including pharmaceutical companies, diagnostic manufacturers, testing laboratories, and food producers—by helping them maintain the highest standards of quality, safety, and regulatory compliance.
“By acquiring DiaMex, we will now have access to a best-in-class product range (Optitrol) that complements our own quality control portfolio,” said Ken Yoon, Executive Vice President and General Manager of LGC’s Diagnostics & Genomics Business Unit. “This will greatly enhance the choice of products we can offer our customers within the core laboratory and blood bank spaces, helping us to drive stronger partnerships together, particularly for our clients in Europe, Asia Pacific, and Latin America.”
“As we continue to seek opportunities to strengthen the portfolio of in vitro diagnostics serology and molecular controls we can offer our clinical laboratory customers, we are delighted to welcome DiaMex to the LGC family,” added Bharathi Anekella, Executive Vice President and leader of LGC’s Diagnostics & Genomics Innovation Hub. “This acquisition will enable us to drive innovation forward much more rapidly and give us a highly differentiated product portfolio.”
Related Links:
LGC
